Author Correction: Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer (Nature Cancer, (2022), 10.1038/s43018-022-00400-2)

Laura M. Spring; Hyo Han; Minetta C. Liu; Erika Hamilton; Hanna Irie; Cesar A. Santa-Maria; James Reeves; Peng Pan; Ming Shan; Yongqiang Tang; Julie R. Graham; Sebastien Hazard; Leif W. Ellisen; Steven J. Isakoff

doi:10.1038/s43018-022-00430-w

Author Correction: Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer (Nature Cancer, (2022), 10.1038/s43018-022-00400-2)

Laura M. Spring, Hyo Han, Minetta C. Liu, Erika Hamilton, Hanna Irie, Cesar A. Santa-Maria, James Reeves, Peng Pan, Ming Shan, Yongqiang Tang, Julie R. Graham, Sebastien Hazard, Leif W. Ellisen, Steven J. Isakoff

Medical Oncology

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

In the version of this article initially published, in the first sentence of the second paragraph now reading “Niraparib is a PARP-1/2 inhibitor approved for recurrent or advanced ovarian cancers,” the word “endometrial” originally appeared in place of “ovarian”. The error has been corrected in the HTML and PDF versions of the article.

Original language	English (US)
Journal	Nature Cancer
DOIs	https://doi.org/10.1038/s43018-022-00430-w
State	Published - Sep 2022

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1038/s43018-022-00430-w

Cite this

Spring, L. M., Han, H., Liu, M. C., Hamilton, E., Irie, H., Santa-Maria, C. A., Reeves, J., Pan, P., Shan, M., Tang, Y., Graham, J. R., Hazard, S., Ellisen, L. W., & Isakoff, S. J. (2022). Author Correction: Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer (Nature Cancer, (2022), 10.1038/s43018-022-00400-2). Nature Cancer. https://doi.org/10.1038/s43018-022-00430-w

Spring, LM, Han, H, Liu, MC, Hamilton, E, Irie, H, Santa-Maria, CA, Reeves, J, Pan, P, Shan, M, Tang, Y, Graham, JR, Hazard, S, Ellisen, LW & Isakoff, SJ 2022, 'Author Correction: Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer (Nature Cancer, (2022), 10.1038/s43018-022-00400-2)', Nature Cancer. https://doi.org/10.1038/s43018-022-00430-w

@article{90eee2c21125446695c2af98c479c4d4,

title = "Author Correction: Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer (Nature Cancer, (2022), 10.1038/s43018-022-00400-2)",

abstract = "In the version of this article initially published, in the first sentence of the second paragraph now reading “Niraparib is a PARP-1/2 inhibitor approved for recurrent or advanced ovarian cancers,” the word “endometrial” originally appeared in place of “ovarian”. The error has been corrected in the HTML and PDF versions of the article.",

author = "Spring, {Laura M.} and Hyo Han and Liu, {Minetta C.} and Erika Hamilton and Hanna Irie and Santa-Maria, {Cesar A.} and James Reeves and Peng Pan and Ming Shan and Yongqiang Tang and Graham, {Julie R.} and Sebastien Hazard and Ellisen, {Leif W.} and Isakoff, {Steven J.}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2022.",

year = "2022",

month = sep,

doi = "10.1038/s43018-022-00430-w",

language = "English (US)",

journal = "Nature Cancer",

issn = "2662-1347",

publisher = "Nature Research",

}

TY - JOUR

T1 - Author Correction

T2 - Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer (Nature Cancer, (2022), 10.1038/s43018-022-00400-2)

AU - Spring, Laura M.

AU - Han, Hyo

AU - Liu, Minetta C.

AU - Hamilton, Erika

AU - Irie, Hanna

AU - Santa-Maria, Cesar A.

AU - Reeves, James

AU - Pan, Peng

AU - Shan, Ming

AU - Tang, Yongqiang

AU - Graham, Julie R.

AU - Hazard, Sebastien

AU - Ellisen, Leif W.

AU - Isakoff, Steven J.

PY - 2022/9

Y1 - 2022/9

N2 - In the version of this article initially published, in the first sentence of the second paragraph now reading “Niraparib is a PARP-1/2 inhibitor approved for recurrent or advanced ovarian cancers,” the word “endometrial” originally appeared in place of “ovarian”. The error has been corrected in the HTML and PDF versions of the article.

AB - In the version of this article initially published, in the first sentence of the second paragraph now reading “Niraparib is a PARP-1/2 inhibitor approved for recurrent or advanced ovarian cancers,” the word “endometrial” originally appeared in place of “ovarian”. The error has been corrected in the HTML and PDF versions of the article.

UR - http://www.scopus.com/inward/record.url?scp=85136469049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85136469049&partnerID=8YFLogxK

U2 - 10.1038/s43018-022-00430-w

DO - 10.1038/s43018-022-00430-w

M3 - Comment/debate

C2 - 35931884

AN - SCOPUS:85136469049

SN - 2662-1347

JO - Nature Cancer

JF - Nature Cancer

ER -

Author Correction: Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer (Nature Cancer, (2022), 10.1038/s43018-022-00400-2)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this